Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456458 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL19557778 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456455 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12377250 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL20143550 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL4023787 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456463 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL277126 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12459875 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL5005939 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665317-A1 | COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4665348-A1 | COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4665327-A1 | COMPOSITIONS COMPRISING 3,4-METHYLENEDIOXYMETHAMPHETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4661877-A1 | COMPOSITIONS COMPRISING PSILOCYBIN, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-20250302773-A1 | COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF | Clearmind Medicine Inc. (CA) | 2025-10-02 | — | — | US | claimed |
| EP-4433022-B1 | LIQUID COMPOSITION OF CERAMIDES AND PALMITIC ACID AMIDES | UNIFARCO S P A (IT) | 2025-06-18 | — | — | EP | claimed |
| US-20250009634-A1 | LIQUID COMPOSITION OF CERAMIDES AND PALMITIC ACID AMIDES | UNIFARCO S.P.A. (IT) | 2025-01-09 | — | — | US | claimed |
| EP-4433022-A1 | LIQUID COMPOSITION OF CERAMIDES AND PALMITIC ACID AMIDES | Unifarco S.p.A. (IT) | 2024-09-25 | — | — | EP | claimed |
| WO-2024171075-A1 | COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-22 | — | — | WO | claimed |
| WO-2024171074-A1 | COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-22 | — | — | WO | claimed |
| US-20200038367-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | THERAPIX BIOSCIENCES, LTD. (IL) | 2020-02-06 | — | — | US | claimed |
| US-20200030281-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | THERAPIX BIOSCIENCES, LTD. (IL) | 2020-01-30 | — | — | US | claimed |
| WO-2019145783-A1 | COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA | Therapix Biosciences Ltd. (IL) | 2019-08-01 | — | — | WO | claimed |
| US-20190183914-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd. (IL) | 2019-06-20 | — | — | US | claimed |
| EP-3484469-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd (IL) | 2019-05-22 | — | — | EP | claimed |
| US-20180116982-A1 | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2018-05-03 | — | — | US | claimed |
| US-20180078523-A1 | COMBINATION OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2018-03-22 | — | — | US | claimed |
| EP-3288553-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd (IL) | 2018-03-07 | — | — | EP | claimed |
| WO-2018011813-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd. (IL) | 2018-01-18 | — | — | WO | claimed |
| WO-2016174661-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2016-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302773-A1 | COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF | SLC18A2, PNMT, DBI | FAAH 83/4885MEN1 886/4885KMT2A 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.